Oric Pharmaceuticals, Inc.

For the period ended Mar 31, 2026. Filed May 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 4, 2026

ORIC$8.82+3.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	March 31, 2026	December 31, 2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$56,396	$45,669
Short-term investments	225,536	235,819
Prepaid expenses and other current assets	8,301	6,978
Total current assets	290,233	288,466
Long-term investments	137,779	110,762
Property and equipment, net	2,147	2,415
Other assets	6,603	7,247
Total assets	$436,762	$408,890
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$2,895	$3,824
Accrued liabilities	14,876	16,593
Total current liabilities	17,771	20,417
Other long-term liabilities	3,434	4,111
Total liabilities	21,205	24,528
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025	—	—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 103,486,412 and 98,528,949 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	11	11
Additional paid-in capital	1,143,845	1,075,807
Accumulated deficit	(728,009)	(692,242)
Accumulated other comprehensive (loss) income	(290)	786
Total stockholders' equity	415,557	384,362
Total liabilities and stockholders' equity	$436,762	$408,890

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.